Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe −/− mice

A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice

(2012) Junichi Matsubara et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Overexpression of Tissue Inhibitor of Metalloproteinase 3 in Macrophages Reduces Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice

(2011) Viviana Casagrande et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

(2011) Zubair Shah et al.   CIRCULATION

Current Advances and Therapeutic Potential of Agents Targeting Dipeptidyl Peptidases-IV, -II, 8/9 and Fibroblast Activation Protein

(2011) Shu-Jen Chen et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata

(2011) Chad E. Brokopp et al.   EUROPEAN HEART JOURNAL

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

(2011) Zubair Shah et al.   VASCULAR PHARMACOLOGY

Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1

(2011) Gian Paolo Fadini et al.   VASCULAR PHARMACOLOGY

Sitagliptin (MK0431) Inhibition of Dipeptidyl Peptidase IV Decreases Nonobese Diabetic Mouse CD4+ T-Cell Migration Through Incretin-Dependent and -Independent Pathways

(2010) S.-J. Kim et al.   DIABETES

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

(2010) M. Arakawa et al.   DIABETES

Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor

(2010) Ö. Erdogdu et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

(2010) Robert Frederich et al.   POSTGRADUATE MEDICINE

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

(2009) Le Thi Kim Chung et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

(2009) Manfredi Rizzo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation

(2009) Kristopher C. Dozier et al.   PEPTIDES

Low Tissue Inhibitor of Metalloproteinases 3 and High Matrix Metalloproteinase 14 Levels Defines a Subpopulation of Highly Invasive Foam-Cell Macrophages

(2008) Jason L. Johnson et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes

(2008) R.G. van Lingen et al.   BRITISH JOURNAL OF DERMATOLOGY

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation

(2008) S.-J. Kim et al.   DIABETES

Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

(2008) Goutam C. Mistry et al.   JOURNAL OF CLINICAL PHARMACOLOGY

SDF-1 (CXCL12) in haematopoiesis and leukaemia: impact of DPP IV/CD26

(2007) Martin Hildebrandt   Frontiers in Bioscience-Landmark